You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠集團(000513.SZ):麗珠製藥廠擬4020萬元自健康元取得阿立哌唑微晶項目

格隆匯7月29日丨麗珠集團(000513.SZ)公佈,公司全資子公司麗珠製藥廠於2021年7月29日與健康元(600380.SH)簽訂了《技術轉讓合同》,健康元擬將其自行研發的阿立哌唑長效肌肉注射劑(400mg)(簡稱“阿立哌唑微晶”)項目轉讓給麗珠製藥廠,麗珠製藥廠同意支付相應的技術祕密轉讓費,總金額為人民幣4020.00萬元。

阿立哌唑微晶屬於新型非典型抗精神分裂症藥物,適應症/臨牀應用主要涉及精神分裂症、雙相障礙、難治性抑鬱症等。根據IQVIA統計數據顯示,國內抗精神分裂症藥物2020年度終端銷售金額約為人民幣65.21億元,未有阿立哌唑長效製劑藥品上市銷售,因此公司認為該項目具有良好的市場潛力,產品上市後可為公司精神類產品營銷佈局打造產品組合高壁壘,為公司未來的營銷策略優化奠定了基礎。

截至該公吿披露日,健康元直接、間接持有並控制公司股權約為44.74%,為公司控股股東,健康元為公司關聯法人,該次交易構成關聯交易。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account